Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility.

"Conflict of interest statement: E. David Crawford is a consultant/adviser to Bayer, MDx, Genomic Health, Janssen Pharmaceuticals, Dendreon and Ferring, and has received grant support from NIH and the University of Colorado Cancer Center. His spouse is an employee at Dendreon.: Neal D. Shore is a consultant/adviser to Amgen, Astellas, Bayer, BNI, Dendreon, Ferring, Janssen Pharmaceuticals, Medivation, Sanofi, Takeda and Tolmar.: Daniel P. Petrylak is a consultant/adviser to Bayer, Bellicum, Dendreon, Sanofi, Johnson & Johnson, Exelixis, Ferring, Millennium, Medivation, Pfizer, Roche Laboratories, and Tyme Pharma-ceuticals, has received research funding from, Oncogenix, Progenics, Johnson & Johnson, Merck, Millennium, Dendreon, Sanofi, Agenysis, Eli Lilly, and Roche Laboratories and has ownership interest/investment in Bellicum and Tyme.: Celestia S. Higano is an adviser for AbbVie, Bayer, BHR Pharma, Dendreon, Emergent BioSolutions, Ferring, Genentech, Medivation, Orion Corporation, Pfizer, Sanofi, MorphoSys, Churchill Pharmaceuticals, Astellas Pharma, Clovis Oncology, PAREXEL International, Blue Earth Diagnostics and Asana Biosciences; and has received institutional research funding from Algeta/Bayer, Aragon Pharmaceuti-cals, AstraZeneca, Dendreon, Emergent BioSolutions, Exelixis, Genentech, Medivation, Millennium, Oncogenex, Sanofi, Teva, Pfizer, Hoffman LaRoche, Gilead Sciences and Janssen Pharmaceuticals.: Charles J. Ryan has received honoraria from Janssen Pharmaceuticals."

"Funding: Writing assistance was funded by Janssen Scientific Affairs, LLC."